Collateral sensitivity as a strategy against cancer multidrug resistance.
暂无分享,去创建一个
Michael M Gottesman | Matthew D Hall | M. Gottesman | M. Hall | R. Callaghan | Richard Callaghan | Kristen M. Pluchino | Kristen M Pluchino | Andrew S Goldsborough | A. Goldsborough
[1] Suneet Shukla,et al. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter , 2007, Molecular Cancer Therapeutics.
[2] Elizabeth Fox,et al. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor , 2007, Expert review of anticancer therapy.
[3] J. Bentley,et al. The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation. , 1997, Cancer letters.
[4] H. Sies,et al. Toxic drug effects associated with oxygen metabolism: Redox cycling and lipid peroxidation , 1981, Experientia.
[5] T. Tsuruo,et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.
[6] K. Lee,et al. Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity. , 2008, Journal of medicinal chemistry.
[7] Shufeng Zhou,et al. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[8] M. Bebawy,et al. Modulation of P-glycoprotein-Mediated Anticancer Drug Accumulation, Cytotoxicity, and ATPase Activity by Flavonoid Interactions , 2011, Nutrition and cancer.
[9] A. di Pietro,et al. Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1. , 2010, Bioorganic & medicinal chemistry.
[10] E. Georges,et al. A Mechanism for P-Glycoprotein-Mediated Apoptosis As Revealed by Verapamil Hypersensitivity , 2003 .
[11] Alexander Sedykh,et al. Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues. , 2010, Journal of medicinal chemistry.
[12] Alan Ashworth,et al. Searching for synthetic lethality in cancer. , 2011, Current opinion in genetics & development.
[13] M. Gottesman,et al. Is resistance useless? Multidrug resistance and collateral sensitivity. , 2009, Trends in pharmacological sciences.
[14] Po-Cheng Chiang,et al. A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways. , 2011, Biochemical pharmacology.
[15] A. di Pietro,et al. Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1 , 2004, Cancer Research.
[16] D. Richardson,et al. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. , 2004, Blood.
[17] S. Bates,et al. The challenge of exploiting ABCG2 in the clinic. , 2011, Current pharmaceutical biotechnology.
[18] P. Rieu,et al. Treatment of cystinuria , 1999, Pediatric Nephrology.
[19] S. Cole,et al. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). , 2000, The Journal of pharmacology and experimental therapeutics.
[20] Peng Huang,et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.
[21] M. Gottesman,et al. Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. , 2011, Journal of medicinal chemistry.
[22] R. Lyon,et al. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. , 1988, Cancer research.
[23] Doriane Lorendeau,et al. Identification of Xanthones as Selective Killers of Cancer Cells Overexpressing the ABC Transporter MRP1 , 2011, ChemMedChem.
[24] T. Tsuruo,et al. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. , 1983, Cancer research.
[25] L. Helson. Calcium channel blocker enhancement of anticancer drug cytotoxicity--a review. , 1984, Cancer drug delivery.
[26] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[27] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[28] A. Calcagno,et al. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. , 2007, Current drug delivery.
[29] D. Richardson,et al. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.
[30] M. Clynes,et al. Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants. , 2004, Anticancer research.
[31] D. Richardson,et al. The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.
[32] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[33] Yu-Ying He,et al. Role of Reduced Glutathione Efflux in Apoptosis of Immortalized Human Keratinocytes Induced by UVA* , 2003, The Journal of Biological Chemistry.
[34] Robert W. Robey,et al. A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer , 2010, Clinical Cancer Research.
[35] Michael M Gottesman,et al. Structure of a multidrug transporter , 2009, Nature Biotechnology.
[36] E. Georges,et al. P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil. , 2009, Archives of biochemistry and biophysics.
[37] T. Mak,et al. Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.
[38] Chi V. Dang,et al. Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.
[39] M. Gottesman,et al. Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. , 2011, Journal of medicinal chemistry.
[40] D. Richardson,et al. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. , 2004, Blood.
[41] Ida Landini,et al. Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression , 2012, Medicinal research reviews.
[42] J. Warr,et al. Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells. , 1988, Cancer research.
[43] M. Gottesman,et al. Identification of compounds selectively killing multidrug-resistant cancer cells. , 2009, Cancer research.
[44] J. Jaffrezou,et al. Verapamil decreases P‐glycoprotein expression in multidrug‐resistant human leukemic cell lines , 1994, International journal of cancer.
[45] K. Marks,et al. The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 Enzymes , 2011, Journal of natural products.
[46] J. Riordan,et al. Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane. , 1995, Biochimica et biophysica acta.
[47] John N Weinstein,et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.
[48] M. Gottesman,et al. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. , 2003, Cancer research.
[49] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[50] M. Gottesman,et al. The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. , 1991, Cancer research.
[51] D. Quinn,et al. 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. , 1998, British Journal of Cancer.
[52] T. Tsuruo,et al. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. , 1989, Cancer research.
[53] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[54] Scott E. Martin,et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. , 2006, Cancer research.
[55] G. Navon,et al. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. , 1990, Cancer research.
[56] D. Richardson,et al. The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study. , 2010, Journal of inorganic biochemistry.
[57] T. Fojo,et al. The role of ABC transporters in clinical practice. , 2003, The oncologist.
[58] A. E. Senior,et al. Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. , 1993, The Journal of biological chemistry.
[59] S. K. Choudhuri,et al. Targeting Mitochondrial Cell Death Pathway to Overcome Drug Resistance with a Newly Developed Iron Chelate , 2010, PloS one.
[60] Prisant Lm. Verapamil revisited: a transition in novel drug delivery systems and outcomes. , 2001 .
[61] J. Lankelma,et al. Induction by verapamil of a rapid increase in ATP consumption in multidrug‐resistant tumor cells , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] S. Bates,et al. ABCG2: determining its relevance in clinical drug resistance , 2007, Cancer and Metastasis Reviews.
[63] S. Cole,et al. Transport of glutathione and glutathione conjugates by MRP1. , 2006, Trends in pharmacological sciences.
[64] A. di Pietro,et al. (R)- and (S)-Verapamil Differentially Modulate the Multidrug-resistant Protein MRP1* , 2007, Journal of Biological Chemistry.
[65] W. Berger,et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications , 2005, Journal of Cancer Research and Clinical Oncology.
[66] F. Brewer,et al. Verapamil hypersensitivity of vincristine resistant Chinese hamster ovary cell lines. , 1986, Cell biology international reports.
[67] J. Till,et al. Pleiotropic phenotype of colchicine‐resistant CHO cells: Cross‐resistance and collateral sensitivity , 1976, Journal of cellular physiology.
[68] J. Riordan,et al. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. , 1987, Biochemical pharmacology.
[69] I. Pastan,et al. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs , 1985, Somatic cell and molecular genetics.
[70] Gergely Szakács,et al. Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. , 2009, Journal of medicinal chemistry.
[71] W. Szybalski,et al. GENETIC STUDIES ON MICROBIAL CROSS RESISTANCE TO TOXIC AGENTS I. , , 1952, American review of tuberculosis.